YAP plays a crucial role in KRAS-mutation-driven tumorigenesis of pancreatic ductal adenocarcinoma [30], and we previously identified that YAP/TAZ expressions participate in the resistance of anti-EGFR therapy in KRAS-mutant NSCLC [26]. This evidence concerns the gene YAP1 and non-small cell lung carcinoma.